Boston Scientific (BSX) Faces Cyberattack And Recall Fallout, Is The Sell Off Overdone?
Why Boston Scientific stock is in focus now
Boston Scientific (BSX) is back on many watchlists after an August cyberattack disrupted manufacturing and shipping, followed by voluntary worldwide recalls of its LUX-Dx insertable cardiac monitors over delayed AF Burden Alert notifications.
Recent setbacks have hit sentiment hard. Boston Scientific’s share price is up 4.82% over the past day but still down 13.08% over 30 days and 52.43% year to date, while the 1 year total shareholder return has declined 54.89%, signaling pressure on the story despite prior multi year gains.
Scan how investors are repricing Boston Scientific’s risk, then size up other medical device stocks facing similar pressure in our curated 11 resilient stocks with low risk scores list built for resilience under stress.
Boston Scientific still runs a large, diversified medical device operation that generated US$20.996b in revenue and US$3.674b in net income. Yet after the cyberattack and recalls, is that underlying engine now being valued sensibly or not?
Most Popular Narrative: 28% Undervalued
Boston Scientific last closed at $45.05 while the most followed narrative pegs fair value near $62.69. The current sell off therefore sits against a framework that still sees meaningful fundamental support for the equity story.
Investment in proprietary, high-margin technologies (for example, next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.
See why 76 investors see Boston Scientific as 28% undervalued.
Result: Fair Value of $62.69 (UNDERVALUED)
Still, Boston Scientific’s story can break if Watchman and electrophysiology headwinds persist, or if further recalls and regulatory scrutiny undermine confidence in key franchises.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
Sentiment around Boston Scientific is split, which is why this may be an important moment to quickly develop your own view using the full picture of 4 key rewards and 1 important warning sign.
Looking for more Boston Scientific sized ideas?
If Boston Scientific has sharpened your eye for risk and reward, do not stop here. Fresh opportunities often emerge where sentiment has not yet caught up.
- Target quality at a discount by scanning companies that screen as 35 high quality undervalued stocks and compare their stories with what you see in Boston Scientific.
- Prioritise resilience by focusing on businesses in our list of solid balance sheet and fundamentals (23 results) so you are not relying solely on future promises to support your thesis.
- Get ahead of the crowd by hunting through 15 high quality undiscovered gems that combine strong fundamentals with lower visibility before everyone else starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com